专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010015849A3 PYRAZOLO [3,4] PYRIMIDIN-4-YL DERIVATIVES AND THEIR USES TO TREAT DIABETES AND OBESITY 审中-公开
标题翻译：吡咯并[3,4]吡咯烷-4-YL衍生物及其用于治疗糖尿病和肥胖症的用途
公开(公告)号：WO2010015849A3
公开(公告)日：2010-04-01
申请号：PCT/GB2009050970
申请日：2009-08-03
申请人： ASTRAZENECA AB , ASTRAZENECA UK LTD , BENNETT STUART NORMAN LILE , BONN PETER GUSTAF , BRINK MIKAEL DAN , BUTLIN ROGER JOHN , CAMPBELL LEONIE , DAVIES ROBERT DARREN MORSE , FAEGERHAG JONAS RICKARD , JURVA ULRIK , POINTON HELEN CLAIRE , ROBB GRAEME RICHARD , SCHNECKE VOLKER , SVENSSON HENRIKSSON ANETTE MAR , WALKER ROLF PETER , WARING MICHAEL JAMES , WESTERLUND CHRISTER RALF
发明人： BENNETT STUART NORMAN LILE , BONN PETER GUSTAF , BRINK MIKAEL DAN , BUTLIN ROGER JOHN , CAMPBELL LEONIE , DAVIES ROBERT DARREN MORSE , FAEGERHAG JONAS RICKARD , JURVA ULRIK , POINTON HELEN CLAIRE , ROBB GRAEME RICHARD , SCHNECKE VOLKER , SVENSSON HENRIKSSON ANETTE MARIE , WALKER ROLF PETER , WARING MICHAEL JAMES , WESTERLUND CHRISTER RALF
IPC分类号： C07D487/04 , A61K31/519 , A61P3/04 , A61P3/10
CPC分类号： C07D487/04
摘要： A compound of Formula (I) is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
摘要翻译：式（I）的化合物可用于治疗或预防通过葡萄糖激酶（GLK或GK）介导的疾病或医学病症，导致胰岛素分泌的葡萄糖阈值降低。

2. 发明申请

WO2008050101A2 CHEMICAL COMPOUNDS 审中-公开
标题翻译：化学化合物
公开(公告)号：WO2008050101A2
公开(公告)日：2008-05-02
申请号：PCT/GB2007004018
申请日：2007-10-22
申请人： ASTRAZENECA AB , ASTRAZENECA UK LTD , CAMPBELL LEONIE , PIKE KURT GORDON , SULEMAN ABID , WARING MICHAEL JAMES
发明人： CAMPBELL LEONIE , PIKE KURT GORDON , SULEMAN ABID , WARING MICHAEL JAMES
CPC分类号： C07D401/14 , C07D403/12 , C07D403/14 , C07D411/14 , C07D413/14 , C07D417/14 , C07D419/14
摘要： The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R 1 , A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).
摘要翻译：本发明涉及一组新的式（I）化合物或其盐：其中R 1，A和HET-1如说明书中所述，其可用于治疗或预防通过葡萄糖激酶（GLK）如2型糖尿病介导的疾病或医学病症。本发明还涉及包含所述化合物的药物组合物，使用所述化合物治疗由GLK介导的疾病的方法和制备式（I）化合物的方法。

3. 发明专利

CO6160318A2 COMPUESTOS DE BENZOIL AMINO HETEROCICLIL UTILES EN EL TRATAMIENTO DE UNA ENFERMEDAD MEDIADA A TRAVES DE GLK 未知
公开(公告)号：CO6160318A2
公开(公告)日：2010-05-20
申请号：CO09039732
申请日：2009-04-20
申请人： ASTRAZENECA AB
发明人： CAMPBELL LEONIE , PIKE KURT GORDON , SULEMAN ABID , WARING MICHAEL JAMES
IPC分类号： A61K31/5355 , A61K31/553 , A61K31/554 , A61P3/10 , C07D401/14 , C07D403/12 , C07D403/14 , C07D411/14 , C07D419/14
摘要： 1.- Un compuesto de la Fórmula (I):donde: R1 es seleccionado de (1-4C)alquil y (3-6C)cicloalquil; HET-1 es un anillo heteroaril unido al C de 5 ó 6 miembros que contiene un átomo de nitrógeno en la posición 2 en relación con el nitrógeno amida al cual el anillo está unido y opcionalmente 1 ó 2 heteroátomos del anillo adicionales independientemente seleccionados de O, N y S; dicho anillo es opcionalmente sustituido en cualquier átomo de nitrógeno (siempre que no sea cuaternizado de esta manera) por un sustituyente seleccionado de R7 y/o en 1 ó 2 átomos de carbono disponibles por un sustituyente independientemente seleccionado de R6;El Anillo A es seleccionado de fenil, HET-2 y HET-3; donde si el Anillo A es fenil este es sustituido por R2 y además opcionalmente sustituido por un grupo seleccionado de R3;R2 es seleccionado de -C(O)NR4R5, SOpR4, y -SO2NR4R5; R3 es seleccionado de halo, metil y trifluorometil;R4 es seleccionado de hidrógeno, (1-4C)alquil [opcionalmente sustituido por 1 ó 2 sustituyentes independientemente seleccionados de HET-5, -OR5, -SO2R5, (3-6C)cicloalquil (opcionalmente sustituido con 1 grupo seleccionado de R15) y -C(O)NR5R5], (3- 6C)cicloalquil (opcionalmente sustituido con 1 grupo seleccionado de R15) y HET-5; HET-5 es un anillo heterociclil unido al C o N de 4, 5 ó 6 miembros que contiene 1, 2, 3 ó 4 heteroátomos independientemente seleccionados de O, N y S, donde un grupo -CH2- puede opcionalmente ser reemplazado por un -C(O)-, y donde un átomo de azufre en el anillo heterocíclico puede opcionalmente ser oxidado a un grupo S(O) o S(O)2; dicho anillo es opcionalmente sustituido en un átomo de carbono o nitrógeno disponible por 1 ó 2 sustituyentes (1-4C)alquil; R5 es hidrógeno o (1-4C)alquil;o R4 y R5 junto con el átomo de nitrógeno al cual están unidos forman un anillo heterociclil saturado o parcialmente insaturado de 4 a 7 miembros, que contiene opcionalmente 1 ó 2 heteroátomos adicionales (además del átomo de N de unión) independientemente seleccionados de O, N y S, ...

4. 发明专利

NO20091599A 未知
公开(公告)号：NO20091599A
公开(公告)日：2009-07-21
申请号：NO20091599
申请日：2009-04-22
申请人： ASTRAZENECA AB
发明人： PIKE KURT GORDON , WARING MICHAEL JAMES , CAMPBELL LEONIE , SULEMAN ABID
IPC分类号： C07D401/14 , A61K31/4155 , A61K31/497 , A61P3/10 , C07D403/12 , C07D403/14 , C07D413/14 , C07D417/14
CPC分类号： C07D401/14 , C07D403/12 , C07D403/14 , C07D411/14 , C07D413/14 , C07D417/14 , C07D419/14

5. 发明专利

CA2667435A1 CHEMICAL COMPOUNDS 未知
公开(公告)号：CA2667435A1
公开(公告)日：2008-05-02
申请号：CA2667435
申请日：2007-10-22
申请人： ASTRAZENECA AB
发明人： SULEMAN ABID , PIKE KURT GORDON , WARING MICHAEL JAMES , CAMPBELL LEONIE
IPC分类号： C07D401/14 , A61K31/4155 , A61K31/444 , A61K31/497 , A61K31/5355 , A61K31/553 , A61K31/554 , A61P3/10 , C07D403/12 , C07D403/14 , C07D411/14 , C07D413/14 , C07D417/14 , C07D419/14
摘要： The invention relates to a novel group of compounds of Formula (I) or a s alt thereof: wherein R1, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical c ondition mediated through glucokinase (GLK) such as type 2 diabetes. The inv ention also relates to pharmaceutical compositions comprising said compounds , methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).

7. 发明专利

ZA201101663B PYRAZOLO [3,4D] PYRIMIDIN-4-YL DERIVATIVES AND THEIR USES TO TREAT DIABETES AND OBESITY 未知
公开(公告)号：ZA201101663B
公开(公告)日：2011-11-30
申请号：ZA201101663
申请日：2011-03-03
申请人： ASTRAZENECA AB
发明人： BENNETT STUART NORMAN LILE , BRINK MIKAEL DAN , CAMPBELL LEONIE , FAGERHAG JONAS RICKARD , POINTON HELEN CLAIRE , SCHNECKE VOLKER , WALKER ROLF PETER , WESTERLUND CHRISTER RALF , BONN PETER GUSTAF , BUTLIN ROGER JOHN , DAVIES ROBERT DARREN MORSE , JURVA ULRIK , ROBB GRAEME RICHARD , SVENSSON HENRIKSSON ANETTE MARIE , WARING MICHAEL JAMES
IPC分类号： A61K20060101 , A61P20060101 , C07D20060101
摘要： A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.

8. 发明专利

AU2009278929A1 Pyrazolo (3,4) pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity 未知
公开(公告)号：AU2009278929A1
公开(公告)日：2010-02-11
申请号：AU2009278929
申请日：2009-08-03
申请人： ASTRAZENECA AB
发明人： BENNETT STUART NORMAN LILE , BONN PETER GUSTAF , BRINK MIKAEL DAN , BUTLIN ROGER JOHN , CAMPBELL LEONIE , DAVIES ROBERT DARREN MORSE , FAGERHAG JONAS RICKARD , JURVA ULRIK , POINTON HELEN CLAIRE , ROBB GRAEME RICHARD , SCHNECKE VOLKER , HENRIKSSON ANETTE MARIE SVENSSON , WALKER ROLF PETER , WARING MICHAEL JAMES , WESTERLUND CHRISTER RALF
IPC分类号： C07D487/04 , A61K31/519 , A61P3/04 , A61P3/10
摘要： A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.

9. 发明专利

NO20091599L 未知
公开(公告)号：NO20091599L
公开(公告)日：2009-07-21
申请号：NO20091599
申请日：2009-04-22
申请人： ASTRAZENECA AB
发明人： PIKE KURT GORDON , WARING MICHAEL JAMES , CAMPBELL LEONIE , SULEMAN ABID
IPC分类号： C07D401/14 , A61K31/4155 , A61K31/497 , A61P3/10 , C07D403/12 , C07D403/14 , C07D413/14 , C07D417/14
摘要： The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).

10. 发明专利

BRPI0718504A2 未知
公开(公告)号：BRPI0718504A2
公开(公告)日：2013-12-03
申请号：BRPI0718504
申请日：2007-10-22
申请人： ASTRAZENECA AB
发明人： CAMPBELL LEONIE , PIKE KURT GORDON , SULEMAN ABID , WARING MICHAEL JAMES
IPC分类号： C07D401/14 , A61K31/4155 , A61K31/444 , A61K31/497 , A61K31/5355 , A61K31/553 , A61K31/554 , A61P3/10 , C07D403/12 , C07D403/14 , C07D411/14 , C07D413/14 , C07D417/14 , C07D419/14
摘要： The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式